Skip to main content
Yantai Zhenghai Bio-Tech Co., Ltd. logo

Yantai Zhenghai Bio-Tech Co., Ltd. — Investor Relations & Filings

Ticker · 300653 ISIN · CNE100002NZ1 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 970 across all filing types
Latest filing 2021-04-08 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300653

About Yantai Zhenghai Bio-Tech Co., Ltd.

https://www.zhbio.com

Yantai Zhenghai Bio-Tech Co., Ltd. specializes in the research, development, production, and sale of regenerative medicine materials. The company focuses on tissue engineering and biomaterials to provide solutions for clinical repair and functional reconstruction. Its core product portfolio includes the Heal-All oral repair membrane, absorbable hard cerebral (spinal) membrane patches, and skin repair membranes. These products are widely utilized in stomatology, neurosurgery, and orthopedics. The company leverages advanced processing technologies to ensure biocompatibility and safety in its medical devices. By integrating research with clinical needs, it develops innovative bone repair materials and other biological scaffolds designed to facilitate natural tissue regeneration.

Recent filings

Filing Released Lang Actions
2020年度控股股东及其他关联方占用资金情况审核报告
Audit Report / Information Classification · 95% confidence The document is titled as an audit report on the situation of funds occupied by controlling shareholders and other related parties for the year 2020. It is issued by a certified public accounting firm and includes an audit opinion, responsibilities of management and auditors, and a detailed summary table of the fund occupation. The document references the 2020 fiscal year and is a standalone audit report focusing on a specific aspect of the company's financial dealings, not a full annual report or interim report. It is not a brief announcement or a certification letter but a detailed audit report. Therefore, it fits the category of Audit Report / Information (AR). The document length is 3240 characters, which is consistent with a detailed audit report rather than a short announcement. FY 2020
2021-04-08 Chinese
独立董事候选人声明（宋希亮）
Board/Management Information Classification · 95% confidence The document is a detailed declaration by an independent director candidate for a company, outlining compliance with various legal and regulatory requirements for serving as an independent director. It includes statements of qualifications, independence, and adherence to relevant laws and stock exchange rules. There is no financial data, no report of financial results, no voting results, no management changes, no earnings or capital updates, and no mention of any report publication. The content is focused on governance and compliance related to board membership qualifications. Therefore, this document fits best under the category of Board/Management Information (MANG), as it relates to the nomination and qualifications of a board member candidate.
2021-04-08 Chinese
2020年度募集资金存放与使用情况专项报告
Capital/Financing Update Classification · 95% confidence The document is titled '2020年度募集资金存放与使用情况专项报告' which translates to '2020 Annual Report on the Storage and Use of Raised Funds'. It details the amount of funds raised, their usage, balances, and compliance with regulatory requirements. It references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange, and includes detailed tables on fund usage and balances. The document is a specialized report focused on the management and use of capital raised by the company, not a general annual report or earnings release. This matches the description of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document length is about 5597 characters, which is substantive and contains detailed financial data related to fundraising usage, not just an announcement or summary. Therefore, the appropriate classification is CAP with high confidence.
2021-04-08 Chinese
关于召开2020年年度股东大会的通知
AGM Information Classification · 100% confidence The document is a detailed notice for the 2020 Annual General Meeting (AGM) of 烟台正海生物科技股份有限公司, including the meeting date, agenda items, voting procedures, and registration details. It contains no financial statements or results but focuses on informing shareholders about the meeting logistics and proposals to be voted on, such as board elections and financial report approvals. This matches the definition of AGM Information (AGM-R), which includes presentations and materials shared during the AGM. The document is lengthy (8714 characters) and is not merely an announcement of a report publication, so it is not an RPA. It is not a voting results declaration (DVA) since it does not provide voting outcomes. Therefore, the correct classification is AGM Information (AGM-R).
2021-04-08 Chinese
监事会对公司2020年度内部控制自我评价报告的审核意见
Audit Report / Information Classification · 95% confidence The document is titled as the Supervisory Board's audit opinion on the company's 2020 internal control self-evaluation report. It references Chinese company law, internal control standards, and stock exchange guidelines. The content is a formal review and opinion on the internal control self-evaluation report, not the report itself. The document length is short (1073 characters), and it mainly contains the Supervisory Board's audit opinion and signatures, without substantive financial data or the full report. Therefore, it is an Audit Report / Information type filing, as it relates to audit opinions on internal controls but is not a full annual report or financial statement. FY 2020
2021-04-08 Chinese
广发证券股份有限公司关于烟台正海生物科技股份有限公司募投项目结项并将节余募集资金永久补充流动资金的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion from the sponsor (Guangfa Securities) regarding the completion of fundraising projects and the permanent supplementation of surplus raised funds into working capital for Yantai Zhenghai Biotechnology Co., Ltd. It includes detailed information about the fundraising amount, usage, surplus funds, regulatory compliance, and approvals by the board, supervisory committee, and independent directors. The document references regulatory guidelines and approvals but does not present financial statements or quarterly/yearly financial results. It is a formal regulatory compliance and verification report related to fundraising and use of proceeds, not an earnings release, annual report, or interim report. The document length is 3638 characters, which is relatively short but contains substantive content about fundraising project completion and fund usage. This fits best under Capital/Financing Update (CAP) as it updates on the use and management of capital raised through an IPO and the reallocation of surplus funds. It is not a simple announcement or report publication, nor a certification letter, so RNS or RPA are less appropriate. Therefore, the classification is CAP with high confidence.
2021-04-08 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.